SCHEMBL5222813

SCHEMBL5222813

COc1ccc(NC(=O)c2ccc(NS(=O)(=O)c3ccccc3)cc2NC(=O)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 5/20 0.60
PPARG P37231 2/20 0.60
PPARD Q03181 1/20 0.60
GPBAR1 Q8TDU6 1/20 0.60
AVPR2 P30518 3/20 0.56
GPR27 Q9NS67 3/20 0.56
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
TDP1 Q9NUW8 1/20 0.55
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
HPGD P15428 1/20 0.54
CRHBP P24387 1/20 0.54
CYP2C19 P33261 1/20 0.54
HTT P42858 1/20 0.54
CRHR2 Q13324 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226610 0.93 NR1H4 (0.60) NR1H4PPARGPPARDGPBAR1AVPR2
SCHEMBL5223117 0.87 F10 (0.64) NR1H4PPARGPPARDGPBAR1MEN1
SCHEMBL5224050 0.85 NR1H4 (0.60) NR1H4PPARGPPARDGPBAR1MEN1
SCHEMBL5226416 0.85 NR1H4 (0.59) NR1H4PPARGPPARDGPBAR1MEN1
SCHEMBL5229003 0.82 NR1H4 (0.68) NR1H4PPARGPPARDGPBAR1MEN1
SCHEMBL5223218 0.81 NR1H4 (0.73) NR1H4PPARGPPARDGPBAR1MEN1
SCHEMBL5222118 0.81 NR1H4 (0.55) NR1H4PPARGPPARDGPBAR1KDM4E
SCHEMBL5226461 0.80 NR1H4 (0.63) NR1H4PPARGPPARDGPBAR1MEN1
SCHEMBL5223816 0.80 NR1H4 (0.65) NR1H4PPARGPPARDGPBAR1MEN1
SCHEMBL5225715 0.79 F10 (0.76) NR1H4PPARGPPARDGPBAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 NR1H4 2304/4885PPARG 2764/4885PPARD 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.